PMID- 30799801
OWN - NLM
STAT- MEDLINE
DCOM- 20200121
LR  - 20200121
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 19
IP  - 5
DP  - 2019
TI  - Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous 
      Diabetic Rat Model.
PG  - 622-631
LID - 10.2174/1871530319666190225113859 [doi]
AB  - BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease 
      with no cure from drugs and treatment. In China, The Traditional Chinese Medicine 
      (TCM) herbal formulations have been used to treat T2DM for centuries. METHODS: In 
      this study, we proposed a formula called ShenQi Compound (SQC), which has been 
      used in clinical therapeutics in China for several years. We evaluated the effect 
      of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of 
      blood indicators and performing histological observations. Meanwhile, the gene 
      microarray and RT-qPCR experiments were used to explore the molecular mechanism 
      of SQC treatment. In addition, western medicine, sitagliptin was employed as a 
      comparison. RESULTS: The results indicated that SQC and sitagliptin could 
      effectively improve the serum lipid (blood Total Cholesterol (TC) and blood 
      Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and 
      Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response 
      (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean 
      Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest 
      Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and 
      vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect 
      on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR 
      experiments indicated that SQC and sitagliptin may improve the T2DM through 
      affecting the biological functions related to apoptosis and circadian rhythm. 
      Moreover, SQC might be able to influence the mTOR signaling pathway by regulating 
      Pik3r1, Ddit4 expression. CONCLUSION: All these results indicate that SQC is an 
      effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood 
      glucose fluctuation-preventing ability, which might be derived from the 
      regulation of the mTOR signaling pathway.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Liu, Ya
AU  - Liu Y
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Kang, Jian
AU  - Kang J
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Gao, Hong
AU  - Gao H
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Zhang, Xiyu
AU  - Zhang X
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Chao, Jun
AU  - Chao J
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Gong, Guangming
AU  - Gong G
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Yuan, Haipo
AU  - Yuan H
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
FAU - Xie, Chunguang
AU  - Xie C
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu 610072, China.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (shenqi)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Animals
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Experimental/complications/*drug therapy/genetics/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/genetics/metabolism
MH  - Diabetic Nephropathies/prevention & control
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Gene Expression Profiling
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Microarray Analysis
MH  - Rats
MH  - Rats, Wistar
MH  - Sitagliptin Phosphate/therapeutic use
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - blood glucose fluctuation
OT  - gene microarray
OT  - mTOR signaling pathway
OT  - sitagliptin
OT  - traditional Chinese medicine.
EDAT- 2019/02/26 06:00
MHDA- 2020/01/22 06:00
CRDT- 2019/02/26 06:00
PHST- 2019/01/03 00:00 [received]
PHST- 2019/01/19 00:00 [revised]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2020/01/22 06:00 [medline]
PHST- 2019/02/26 06:00 [entrez]
AID - EMIDDT-EPUB-96841 [pii]
AID - 10.2174/1871530319666190225113859 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2019;19(5):622-631. doi: 
      10.2174/1871530319666190225113859.